Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Just Jumped 10%

By Rich Smith - Jul 16, 2021 at 10:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company joins the S&P 500 index next week.

What happened

Shares of coronavirus vaccine hero Moderna (MRNA -3.78%) won a new round of applause this morning, rising 10.4% through 10:10 a.m. EDT.

The reason: Moderna stock is joining the S&P 500.

Arrow angles up on a green stock chart

Image source: Getty Images.

So what

The news broke this morning. With Alexion Pharmaceuticals (ALXN) due to be absorbed into AstraZeneca (AZN -0.39%) soon, a slot is opening up in the S&P 500 index of America's largest publicly traded companies. Moderna has been tapped to fill that spot, and will become part of the index just before trading begins on Wednesday, July 21.  

When this happens, mutual funds and ETFs that track the performance of the S&P 500 will need to buy shares of Moderna in order to accurately reflect the index's composition. Knowing that these companies will be forced to buy Moderna, other investors are front-running that need today, buying the stock in anticipation that the price will get bid up next week.

Now what

Well and good. Traders gonna trade, and if they want to buy Moderna today in hopes of earning a quick profit next week, that's certainly their right. (Although one wonders how much profit remains to be made -- how big a bump will the stock really get next week, after it has already jumped today).

Longer-term investors, meanwhile, have a different, more substantive, and potentially even more lucrative catalyst to look forward to. On Thursday, Aug. 5, Moderna will report its earnings for the fiscal second quarter of 2021. Analysts are forecasting that the vaccine maker will reverse a year-ago loss to record $6.04 EPS on sales of nearly $4.3 billion this quarter -- revenue growth of more than 6,000%!  

Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$186.84 (-3.78%) $-7.34
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.03 (-0.39%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.